A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Latest Information Update: 07 Sep 2023
Price :
$35 *
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Alopecia areata
- Focus Registrational; Therapeutic Use
- Sponsors Reistone Biopharma
- 01 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Oct 2023.
- 01 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Aug 2021 New trial record